ReviewRisk analysis : an official publication of the Society for Risk Analysis2021
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
Review in Risk analysis : an official publication of the Society for Risk Analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens (Basel, Switzerland) · 2024Pooled it
- Pooled it
- Impact of the COVID-19 pandemic on number of deaths in Ghana: an application of ARIMA with intervention analysis.Frontiers in public health · 2025Article
- Modeling Poliovirus Transmission and Responses in New York State.The Journal of infectious diseases · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- Nexus between drivers of COVID-19 and country risks.Socio-economic planning sciences · 2023Article
- Review on Approved and Inprogress COVID-19 Vaccines.Iranian journal of pharmaceutical research : IJPR · 2022Review
- COVID-19: Some unresolved issues.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative.Gates open research · 2022Article
- Prioritizing Multidimensional Interdependent Factors Influencing COVID-19 Risk.Risk analysis : an official publication of the Society for Risk Analysis · 2022Review
- Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?Sudanese journal of paediatrics · 2022Review
- One vaccine to counter many diseases? Modeling the economics of oral polio vaccine against child mortality and COVID-19.Frontiers in public health · 2022Article
- NIAID workshop on secondary vaccine effects.Nature immunology · 2021Article
- Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.Innovation (Cambridge (Mass.)) · 2021Review
- Covid-19 deaths in Africa: prospective systematic postmortem surveillance study.BMJ (Clinical research ed.) · 2021Article
- An Updated Economic Analysis of the Global Polio Eradication Initiative.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Modeling and Managing Poliovirus Risks: We are Where we are….Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.].Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 led to a recent high-profile proposal to reintroduce oral poliovirus vaccine (OPV) in the United States (U.S.), initially in clinical trials, but potentially for widespread and repeated use. We explore logistical challenges related to U.S. OPV administration in 2020, review the literature related to nonspecific effects of OPV to induce innate immunity, and model the health and economic implications of the proposal. The costs of reintroducing a single OPV dose to 331 million Americans would exceed $4.4 billion. Giving a dose of bivalent OPV to the entire U.S. population would lead to an expected 40 identifiable cases of vaccine-associated paralytic polio, with young Americans at the highest risk. Reintroducing any OPV use in the U.S. poses a risk of restarting transmission of OPV-related viruses and could lead to new infections in immunocompromised individuals with B-cell related primary immunodeficiencies that could lead to later cases of paralysis. Due to the lack of a currently licensed OPV in the U.S., the decision to administer OPV to Americans for nonspecific immunological effects would require purchasing limited global OPV supplies that could impact polio eradication efforts. Health economic modeling suggests no role for reintroducing OPV into the U.S. with respect to responding to COVID-19. Countries that currently use OPV experience fundamentally different risks, costs, and benefits than the U.S. Successful global polio eradication will depend on sufficient OPV supplies, achieving and maintaining high OPV coverage in OPV-using countries, and effective global OPV cessation and containment in all countries, including the U.S.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.